Latest Breaking News On - Edna kaplan - Page 6 : comparemela.com

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium s Dosing Regimens in Multiple Sclerosis

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for.

United statesEdna kaplanDaniel vittJessica breuPaula schwartzPrnewswire immunic incImmunic incRx communications groupTrademark officeExchange commissionFundamental new patent covers treatmentMultiple sclerosis intoVidofludimus calciumMultiple sclerosisUnless extended furtherProtecting specific dose strength

EQS-News: Immunic, Inc : Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium s Dosing Regimens in Multiple Sclerosis

EQS-News: Immunic, Inc : Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium s Dosing Regimens in Multiple Sclerosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Rheinland pfalzUnited statesEdna kaplanJessica breuStates patentprotecting vidofludimusDaniel vittPaula schwartzImmunic incDistribution servicesExchange commissionRx communications groupTrademark officeReceives noticeDosing regimensMultiple sclerosisNew patent covers treatment

Immunic, Inc Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Immunic, Inc Reports Third Quarter 2023 Financial Results and Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPaula schwartzEdna kaplanJessica breuDaniel vittRx communications groupAssociation of european coeliac societiesDevelopment rd expensesExchange commissionAssembly conferenceImmunic incTrademark officeFund immunic intoPositive interim analysisShowed improvementsSerum neurofilament light chain

Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update

– Webcast to be Held at 8:00 am ET on November 14, 2023 – NEW YORK, Nov. 7, 2023 /PRNewswire/ Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered,.

Edna kaplanPaula schwartzJessica breuExchange commissionImmunic incRx communications groupPrnewswire immunic incPrivate securities litigation reform actAnnual reportInvestor relations

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesEdna kaplanJessica breuPaula schwartzDaniel vittRx communications groupImmunic incExchange commissionPrnewswire immunic incDrug administrationTrademark officeReceives noticeUnited states patent protectingRelapsing multiple sclerosisUnited states patentMultiple sclerosis comprising